Abstract
It is estimated that 12–22% of American children—7.5–14 million children—suffer from mental illness and that many of these children might benefit from psychophar-macologic treatment.1 However, the paucity of empirically based studies has limited the use of psychotropics in the treatment of childhood mental disorders. Furthermore, most psychotropics lack approval by the U.S. Food and Drug Administration (FDA) for use in the pediatric population. Although lack of FDA approval does not restrict use, it may contribute to reluctance by clinicians and families to pursue medication treatments.2
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Institute of Medicine: Research on Children and Adolescents with Mental, Behavioral, and Developmental Disorders. Washington, D.C., National Institute of Mental Health, 1990.
FDA: Use of Approved Drugs of Unlabeled Indications. Psychopharma 18: 5, 1982.
Gittelman-Klein R.: Diagnosis and drug treatment of childhood disorders, in Klein D. F., Gittelman R., Quitkin F., and Rifkin A. (eds): Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children. Baltimore, Williams & Wilkins, 1980, p 576.
Biederman J.: Psychopharmacology in children and adolescents, in Wiener J. (eds): Comprehensive Textbook of Child and Adolescent Psychiatry. Washington, D.C., American Psychiatric Press, 1991, p 545.
Spencer T., Wilens T., Biederman J.: Psychotropic medication for children and adolescents. Child Adolesc Psychiatr Clin North Am 1: 97, 1995.
Clein P., Riddle M.: Pharmacokinetics in children and adolescents. Child Adolesc Psychiatr Clin North Am 1: 59, 1995.
Barkley R. A.: Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York, Guilford Press, 1990.
Biederman J., Baldessarini R., Wright V., et al: A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder II: Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 28: 903, 1989.
Biederman J.: Sudden death in children treated with a tricyclic antidepressant: A commentary. J Am Acad Child Adolesc Psychiatry 30: 495, 1991.
Wilens T. E., Biederman J., Baldessarini R. J., et al: Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 31: 691, 1992.
Riddle M. A., Nelson J. C., Kleinman C. S., et al: Sudden death in children receiving norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30: 104, 1991.
Biederman J., Thisted R., Greenhill L., et al: An epidemiological evaluation of the association between tricyclic antidepressants and the risk for sudden death in five to 14 year-old children. J Clin Psych 56: 87–93, 1995.
Casat C. D., Pleasants D. Z., Schroeder D. H., et al: Bupropion in children with attention deficit disorder. Psychopharma 25: 198, 1989.
Hunt R., Arnsten A., Asbell M.: An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34: 50, 1994.
Ryan N. D., Puig-Antich J., Ambrosini P., et al: The clinical picture of major depression in children and adolescents. Arch Gen Psychiatry 44: 854, 1987.
Anderson J. C., Williams S., McGee R., et al: DSM-III disorders in preadolescent children: Prevalence in a large sample from the general population. Arch Gen Psychiatry 44: 69, 1987.
Kashani J. H., Orvaschel H.: Anxiety disorders in mid-adolescence: A community sample. Am J Psychiatry 145: 960, 1988.
Biederman J., Faraone S., Mick E., et al: Psychiatric comorbidity among referred juveniles with major depression: Fact or artifact. J Am Acad Child Adolesc Psychiatry 34: 579, 1995.
Puig-Antich J.: Major depression and conduct disorder in prepuberty. J Am Acad Child Adolesc Psychiatry 21: 118, 1982.
Kovacs M., Feinberg T., Crouse-Novak M., et al: Depressive disorders in childhood: II. A longitudinal study of the risk for a subsequent major depression. Arch Gen Psychiatry 41: 643, 1984.
Biederman J., Faraone S. V., Keenan K., et al: Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder (ADHD): Patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 49: 728, 1992.
Geller B., Cooper T. B., Graham D. L., et al: Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6–12 year olds with major depressive disorder: Outcome; nortiptyline and hydroxy-nortriptyline plasma levels; EKG, BP and side effects measurements. J Am Acad Child Adolesc Psychiatry 31: 34, 1992.
Puig-Antich J., Perel J. M., Lupatkin W., et al: Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry 44: 81, 1987.
Wozniak J., Biederman J., Kiely K., et al: Mania-like symptoms suggestive of childhood onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry 34: 867, 1995.
Alessi N., Naylor M., Ghaziuddin M., et al: Update on lithium carbonate therapy in children and adolescents. J Am Acad Child Adolesc Psychiatry 33: 291, 1994.
Leonard H. L., Swedo S. E., Rapoport J. L., et al: Treatment of obsessive compulsive disorder with clomipramine and desipramine in children and adolescents: A double-blind crossover comparison. Arch Gen Psychiatry 46: 1088, 1989.
Rapoport J., Swedo S., Leonard H.: Childhood obsessive compulsive disorder. J Clin Psychiatry 53: 11, 1992.
Riddle M., Scahill L., King R., et al: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31: 1062, 1992.
Geller D. A., Biederman J., Reed E. D., et al: Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34: 36, 1994.
Leckman J. F., Hardin M. T., Riddle M. A., et al: Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 48: 324, 1991.
Riddle M. A., Hardin M. T., Cho S. C., et al: Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 27: 811, 1988.
Singer H. S., et al: The treatment of attention-deficit hyperactivity disorder in Tourette syndrome: A double-blind placebo-controlled study with clonidine and desipramine, Pediatrics 95: 74–81.
Spencer T., Biederman J., Kerman K., et al: Desipramine in the treatment of children with Tic disorder or Tourette’s Syndrome and attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 32: 354, 1993.
Jankovic J.: Deprenyl in attention deficit associated with Tourette’s syndrome. Arch Neurol 50: 286, 1993.
Campbell M., Spencer E. K.: Psychopharmacology in child and adolescent psychiatry: A review of the past five years. J Am Acad Child Adolesc Psychiatry 27: 269, 1988.
Rapoport J.: Clozapine and child psychiatry. J Child Adolesc Psychopharmacol 4: 1, 1994.
Frazier J., Gordon C. T., McKenna K., et al: An open trial of clozapine in 11 adolescents with childhood onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33: 658, 1994.
Wilens T., Biederman J., Spencer T.: Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 33: 424, 1994.
Biederman J., Newcorn J., Sprich S.: Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148: 564, 1991.
Bird H. R., Canino G., Rubio-Stipec M., et al: Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. Arch Gen Psychiatry 45: 1120, 1988.
Rapport M. D., Carlson G. A., Kelly K. L., et al: Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 32: 333, 1993.
Wilens T. E., Biederman J., Geist D. E., et al: Nortriptyline in the treatment of attention deficit hyperactivity disorder: A chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32: 343, 1993.
Wilens T., Spencer T., Biederman J., et al: Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 34: 110, 1994.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wozniak, J., Biederman, J., Spencer, T., Wilens, T. (1998). Pediatric Psychopharmacology. In: Gelenberg, A.J., Bassuk, E.L. (eds) The Practitioner’s Guide to Psychoactive Drugs. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5877-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5877-4_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7695-8
Online ISBN: 978-1-4615-5877-4
eBook Packages: Springer Book Archive